How have pre-submission meetings for generic drug applicants changed under GDUFA III?

BY RACHEL COE, MSC

Under GDUFA III, the scope and purpose of pre-submission meetings for generic drug developers has changed. During a meeting this week, FDA speakers highlighted the uniqueness of this redesigned meeting type in allowing sponsors to explain how they’ve addressed challenges encountered during product development.

Fill out the form to read the full article.